AQST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aquestive Therapeutics Inc (AQST) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite some positive aspects, such as a potential recovery path for its key drug Anaphylm and improved financial metrics, the stock faces significant legal challenges, insider selling, and a lack of immediate growth catalysts. Holding the stock for now would be a more prudent approach.
The MACD is positive and expanding, indicating a slight bullish momentum. RSI is neutral at 59.362, and moving averages are converging, showing no clear trend. Key support is at 3.982, and resistance is at 4.257. The stock is trading near its pivot level of 4.119, suggesting limited immediate upside.
Analysts maintain a Buy rating despite price target reductions, showing confidence in the company's long-term potential.
The FDA's Complete Response Letter for Anaphylm appears addressable with no major concerns, and the company has an aggressive plan for resubmission by Q3 2026.
Multiple class action lawsuits alleging securities fraud and misrepresentation regarding the New Drug Application.
Insider selling has increased significantly by 140.84% in the last month.
Delayed approval of Anaphylm introduces clinical and commercial risks, with no immediate revenue boost expected.
Lack of significant hedge fund activity and neutral sentiment from institutional investors.
In Q4 2025, revenue grew by 9.67% YoY to $13.015M, and net income improved by 86.81% YoY, though it remains negative at -$31.86M. EPS improved by 36.84% YoY to -0.26. However, gross margin declined by 10.90% YoY to 55.16%, indicating cost pressures.
Analysts have lowered their price targets recently (Alliance Global: $9 from $12, Lake Street: $6 from $8) but maintain Buy ratings. Analysts highlight the potential for Anaphylm and other products but acknowledge timeline-driven risks and commercial uncertainties.
